Long-term care executives named Pfizer Inc., New York, the pharmaceutical company that best meets their needs.
Long-term care executives named Pfizer Inc., New York, the pharmaceutical company that best meets their needs, reported market analysts at Newtown, PA-based Scott-Levin.
The company ranked highest in all four assessment categories of Scott-Levin's Spring 1999 Nursing Home Pharmacy Provider/Consultant Promotional Audit. The audit was based on the responses of pharmacy providers and consultants who represent 73% of all nursing home beds in the United States. Respondents made their judgements based on promotional activity by pharmaceutical companies over an eight-week period this past spring.
Pfizer received high marks for contracts, value-added services, knowledgeable representatives and overall service. Panelists also cited Pfizer's aggressive contracts, competitive pricing and support of continuation programs; Pfizer reps' responsiveness and grasp of long-term care issues, including the Medicare prospective payment system; and service to customers.
Johnson & Johnson, Bayer and Novartis maintained their Fall 1998 respective rankings as other companies that satisfied long-term care executives' overall needs. Meanwhile, Abbott continued its rise from 38th in the fall of 1997 to fourth place this spring. Purdue Frederick rose from sixth last fall to tie for fifth with Novartis.
Johnson & Johnson made the most calls to long-term care customers during the spring 1999 audit, with Risperdal® and Levaquin⢠being the company's most promoted drugs. The biggest gains in promotional activity were logged by Searle, which increased its calls by 104% to claim 7th place, and Knoll, which made 59% more calls than in the fall to finish 10th. PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.